

## Issue of Shares on Exercise of Performance Rights

**PERTH, Australia, 10 October 2025:** Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix<sup>®</sup> AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, advises that 200,000 ordinary shares were issued today on the exercise of vested performance rights issued pursuant to the Company's incentive plan.

An Appendix 2A seeking quotation of the shares will be lodged following this announcement.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

### About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit [www.artrya.com](http://www.artrya.com) or follow us on LinkedIn at [www.linkedin.com/company/artrya](http://www.linkedin.com/company/artrya)

### For more information:

#### Corporate Enquiries

**John Konstantopoulos**

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: [contact@artrya.com](mailto:contact@artrya.com)

#### Investor & Media Enquiries

**David Allen or John Granger**

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: [investors@artrya.com](mailto:investors@artrya.com)